Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 646 Issue 8085, 16 October 2025

Starving cancer

Neuroblastoma is a highly lethal childhood cancer that develops in the peripheral nervous system with tumour growth fuelled by the biosynthesis of polyamines. The drug difluoromethylornithine, which inhibits polyamine biosynthesis, was approved in late 2023 to help treat neuroblastoma. In this week’s issue, Sarah Cherkaoui, Raphael Morscher and colleagues probe the action of this drug and reveal that specific dietary restriction can markedly improve its beneficial effects in mice. The researchers found that a diet that eliminated the amino acids proline and arginine decreased the amount of the polyamine precursor ornithine available for synthesis. This, in turn, enhanced polyamine depletion by difluoromethylornithine, which reprogrammed tumour growth and improved survival rates in mice.

Cover image: Avesta Rastan

This Week

Top of page ⤴

News in Focus

Top of page ⤴

Books & Arts

Top of page ⤴

Opinion

Top of page ⤴

Work

Top of page ⤴

Research

Top of page ⤴
Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Quick links